Pacira Pharmaceuticals to Contest Patent Ruling on Exparel, Impacting Nonopioid Pain Management Market

Pacira Pharmaceuticals Inc. has declared its intention to appeal a New Jersey federal judge’s decision that invalidated its patent on Exparel, a nonopioid pain management drug. The ruling potentially paves the way for generic versions of the long-acting injectable used for managing postsurgical pain. The company is contesting the decision, which poses significant implications for its market exclusivity. For further details, refer to the original article.